Good Pharmaceutical Development Co.

GP Therapeutics, officially known as Good Pharmaceutical Development Co., Ltd., is a clinical-stage pharmaceutical company and a key research and development subsidiary of Grand Pharmaceutical Group. The company is dedicated to the development of innovative drugs and medical devices, with a primary focus on ophthalmology, cardiovascular emergencies, and oncology. GP Therapeutics manages a diverse pipeline of products, often acquired through strategic global partnerships and in-licensing agreements. Its lead programs include advanced treatments for pterygium and post-operative ocular inflammation, utilizing specialized delivery technologies such as nanoemulsions. The company plays a critical role in bridging international innovation with the Greater China market through its regulatory expertise and clinical development capabilities. Headquartered in Hong Kong, GP Therapeutics continues to expand its footprint in the global life sciences sector.